Navigation Links
Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
Date:2/20/2008

Conference Call and Webcast to Follow

THE WOODLANDS, Texas, Feb. 20 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its fourth quarter and year end 2007 financial results on Thursday, March 6, 2008 after the financial markets close. Lexicon management will hold a conference call to discuss its clinical development progress, financial results for 2007 and financial guidance for 2008 at 5:00 p.m. Eastern Time on March 6, 2008.

The dial-in number for the conference call is 877-681-3378 (within the United States) or 719-325-4842 (international). The pass code for all callers is 7721341. Investors can access a live webcast of the call at http://www.lexpharma.com. An archived version of the webcast will be available on the website through March 11, 2008.

About Lexicon

Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon currently has development programs underway for such areas of major unmet medical need as irritable bowel syndrome, cognitive disorders, autoimmune diseases, and carcinoid syndrome. The company has used its proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of cardiology, gastroenterology, immunology and oncology, metabolism, neurology and ophthalmology. To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators including Bristol-Myers Squibb Co., Genentech, Inc. and N.V. Organon. For additional information about Lexicon a
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
2. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
3. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
4. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
5. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
6. Lexicon Pharmaceuticals to Present at Bio InvestorForum
7. Lexicon Pharmaceuticals to Present at ThinkEquity ThinkClinic
8. Lexicon Appoints Judith Swain, M.D. to Board of Directors
9. Lexicon Pharmaceuticals to Present at the UBS Global Life Sciences Conference
10. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
11. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... ... August 26, 2015 , ... Lee ... in the development and manufacture of highly valued cardiac markers used in early ... extensive expertise with protein chemistry has led to the development and commercialization of ...
(Date:8/26/2015)... 2015 Intrexon Corporation (NYSE: XON ), ... of its previously announced public offering of common stock, ... their option to purchase an additional 731,707 shares of ... per share.  The exercise of the underwriters, option brought ... by Intrexon to 5,609,756 shares and increased the total ...
(Date:8/26/2015)... , August 26, 2015 After litigating ... Europlasma NV relating to P2i United States ... their dispute in the United States ... the part of either party. As a result of the ... of California dismissed the case without ...
(Date:8/26/2015)... , ... August 26, 2015 , ... The 2015 Epigenomics ... adult stem cell technology start-up company Asymmetrex to share the first report ... of a new biomarker for counting adult tissue stem cells. , With a name ...
Breaking Biology Technology:Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4P2i Settles United States Litigation 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 4
... Spectrometry Application Report , Key Words Sensitivity ... Gargi Choudhary, Thermo Electron Corporation, San Jose, ... Wayne Skinner and Scott Stanley, University of California, Davis , ... Acepromazine is widely used as a sedative in horses. It serves as a ...
... Dirk Chelius, Terry Zhang, and Ken Miller; , ... Key Words Sensitivity Proteomics Finnigan LCQ ... LC/MS/MS , Introduction , ... been pushed downward to levels no one would have thought possible only a ...
... Gargi Choudhary, Tania A. Sasaki, and Julian J. Phillips, ... Chromatography and Mass Spectrometry Application Report ... Ion trap mass spectrometry is widely ... such as for structural elucidation and identification of unknowns in complex ...
Cached Biology Technology:Determination of Acepromazine and its Major Metabolite in Equine Serum by LC-MS/MS using the Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer 2Determination of Acepromazine and its Major Metabolite in Equine Serum by LC-MS/MS using the Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer 3Determination of Acepromazine and its Major Metabolite in Equine Serum by LC-MS/MS using the Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer 4Fully Automated Nano-Electrospray Coupled with a Finnigan LCQ Deca XP Plus for Sub-fmol Proteomic Analysis 2Fully Automated Nano-Electrospray Coupled with a Finnigan LCQ Deca XP Plus for Sub-fmol Proteomic Analysis 3Fully Automated Nano-Electrospray Coupled with a Finnigan LCQ Deca XP Plus for Sub-fmol Proteomic Analysis 4Fully Automated Nano-Electrospray Coupled with a Finnigan LCQ Deca XP Plus for Sub-fmol Proteomic Analysis 5Sensitivity and Quantitation using a Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer 2Sensitivity and Quantitation using a Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer 3
(Date:8/10/2015)... and TELTOW, Germany , August 10, ... (SMI), a world leader in Eye Tracking Technology for ... its OEM Eye Tracking Platform for integration into all ... contains reference designs for seamless integration of eye tracking ... reality HMDs and augmented reality smart glasses. Omnivision,s leading ...
(Date:8/6/2015)... Germany , August 6, 2015 ... Instruments (SMI) shows the world,s first Eye ... on Epson,s Moverio BT-200 see-through head mounted display and ... solution, unprecedented quality and efficiency is brought to personalized ... For the first time, professionals and researchers can integrate ...
(Date:8/5/2015)... ALBANY, New York , August 5, 2015 /PRNewswire/ ... new market report titled "Facial Recognition Market - Global ... - 2022", the global market for facial recognition is ... market is driven by increased demand for surveillance systems ... to the rising number of crimes and terrorist activities ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6
... 2009 A recent study by Scripps Research Institute scientists ... rare genetic disorder, cystinosis. In research that holds out hope ... fatal disorder, the study shows that the genetic defect in ... "After meeting the children who suffer from this disease, like ...
... 09/17/09) NRL,s Marine Meteorology Division has deployed ... (MAARCO) to the National University of Singapore to ... in the Maritime Continent region. NRL is leading ... infer larger aerosol and visibility features from limited ...
... WASHINGTON -- A report released today by the ... launch a new multiagency, multiyear, and multidisciplinary initiative to ... and to accelerate new breakthroughs that could solve some ... areas of food, environment, energy, and health. ...
Cached Biology News:Rare genetic disease successfully reversed using stem cell transplantation 2Rare genetic disease successfully reversed using stem cell transplantation 3NRL begins Southeast Asia study of aerosols linked to global warming 2NRL begins Southeast Asia study of aerosols linked to global warming 3National new biology initiative offers potential for 'remarkable and far-reaching benefits' 2National new biology initiative offers potential for 'remarkable and far-reaching benefits' 3
... HybriCycler Hybridization Oven with circular clear acrylic ... tubes. HC-3000 HybriCycler Oven features microprocessor operation ... feet balance the unit., Carousel rotates ... carousel is ,easily removable , Bottle ...
... The KingFisher magnetic particle based purification ... and DNA/RNA from any sample. They offer ... family comprises three systems- KingFisher, KingFisher mL ... 20 - 1000 l. Each system consists ...
... is specifically engineered for efficient drying down ... a glass cover and a post-trap with ... odor-free processing of samples in ammonium hydroxide., ... Oligos , Comes ...
... Thermo Savant SpeedVac™ Concentrators set the standard ... series SC210A SpeedVac with large chamber uses a ... dry multiple samples in a single run. , ... Rotor Chamber for long lasting chemical compatibility ...
Biology Products: